Ocugen (NASDAQ:OCGN) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Ocugen (NASDAQ:OCGN) issued its earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.05, FiscalAI reports. The company had revenue of $1.95 million during the quarter, compared to analysts’ expectations of $1.32 million.

Here are the key takeaways from Ocugen’s conference call:

• Ocugen completed enrollment in the 140-patient Phase III OCU400 trial for retinitis pigmentosa and expects top-line results in Q1 2027, followed by a planned BLA submission. Management cited supportive earlier-stage results and trial-power analyses, but these do not establish that the pivotal trial will succeed.
• All three late-stage programs are now in Phase III: OCU410 for geographic atrophy dosed its first patient, with enrollment targeted for 2027 and a BLA targeted for 2028; OCU410ST for Stargardt disease is expected to report top-line data in Q2 2027. The company said it remains on track to file three BLAs by 2028.
• For OCU410ST, an independent data monitoring committee recommended continuing the study without changes after a planned interim review. Management said the review involved a small, variable patient group at month eight, and the company remains blinded while it awaits the full month-12 data; the timing of the readout is expected in Q2 2027.
• Ocugen had $84.6 million in cash, restricted cash, and short-term investments at quarter-end and expects its runway to extend into 2028, enough to fund two of three late-stage programs through anticipated BLA filings. Nine-month operating expenses rose to $57 million from $50.5 million a year earlier, leaving funding needs for the remaining program a consideration.
• Ocugen finalized an exclusive OCU400 license for the Middle East and North Africa, with up to $4 million in upfront and potential initial development payments, up to $255 million in sales milestones, and a 22% royalty on net sales. The company also said OCU400 received provisional approval in the Bahamas and expects full approval by year-end, although patient uptake and resulting revenue were not specified.

Ocugen Stock Performance

Ocugen stock traded up $0.11 during midday trading on Wednesday, hitting $0.85. The stock had a trading volume of 6,878,713 shares, compared to its average volume of 7,168,636. Ocugen has a 52-week low of $0.69 and a 52-week high of $2.73. The company has a market capitalization of $289.26 million, a PE ratio of -3.29 and a beta of 2.04. The firm’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.42. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 4.17.

Key Stories Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Management outlined three anticipated Phase III readouts, giving investors several potential clinical catalysts to watch. The update also included a new Middle East licensing deal. Ocugen Q3 2026 earnings call transcript
• Positive Sentiment: Ocugen reported $1.95 million in quarterly revenue, above analyst expectations of $1.32 million. One earnings account also reported a loss of $0.01 per share, narrower than the estimated $0.06 loss. Ocugen Q3 earnings results
• Neutral Sentiment: Another report said Ocugen’s loss was $0.06 per share, in line with consensus, underscoring that coverage differed on the EPS comparison. Revenue nevertheless exceeded estimates. Zacks Q3 earnings report
• Negative Sentiment: The Phase III readouts are future catalysts, not results; the investment case remains dependent on clinical progress and execution of the licensing deal.

Analyst Upgrades and Downgrades

OCGN has been the subject of a number of research reports. Weiss Ratings upgraded shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Insider Transactions at Ocugen

In other Ocugen news, CEO Shankar Musunuri sold 57,264 shares of the firm’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $0.95, for a total transaction of $54,400.80. Following the sale, the chief executive officer directly owned 1,030,771 shares of the company’s stock, valued at $979,232.45. This trade represents a 5.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,051,982 shares of company stock valued at $1,088,801. Corporate insiders own 3.95% of the company’s stock.

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company’s programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen’s pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.